Young child with Doctor

Here in our Media Centre you will find corporate press releases and other useful information for business and financial media

Latest press releases

AstraZeneca announces Non-Executive Board changes
17 February 2015
US District Court decision in PULMICORT RESPULES® (budesonide inhalation suspension) patent litigation
13 February 2015
AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
5 February 2015
AstraZeneca PLC fourth quarter and full year results 2014
5 February 2015
AstraZeneca receives planning consent for new global R&D centre and corporate headquarters in Cambridge, UK
4 February 2015
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform
29 January 2015
Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency
22 January 2015
PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses
14 January 2015
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
12 January 2015
LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations   
19 December 2014
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
18 December 2014
AstraZeneca and Amgen to present detailed results from Phase III AMAGINE-1™ study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis
11 December 2014

Fast facts

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.

Fourth quarter and full year results 2014

5 February 2015

The following slides are available to download for the media.

Download presentation (PDF 1911kb)

Photo and video library

AstraZeneca in Cambridge

Broadcast video

Board and management



Operations and Manufacturing

Research & Development

Sign up to email alerts

Your email address will only be used to provide you with services from AstraZeneca that you requested. You can opt out for email subscriptions any time. Your personal information will not be provided to any third party without your permission.